11/24/20 6:59 AMNasdaq : BCYCBicycle Therapeutics to Present at the 2020 Piper Sandler Healthcare ConferenceBicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle(R)) technology, today announced that management will participate in a fireside chat at the 2020 Piper Sandler Healthcare Conference, which is scheduled to take place from December 1 - 3, 2020. The conference will be held in a virtual meeting format. A recording of the fireside chaRHEA-AIneutral
11/20/20 4:05 PMNasdaq : BCYCBicycle Therapeutics Announces Settlement of Patent Dispute with Pepscan Systems B.V.Bicycle Therapeutics plc (NASDAQ:BCYC), a clinical-stage biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle(R)) technology, today announced that it has entered into a settlement and license agreement with Pepscan Systems B.V. regarding Bicycle's use of Pepscan's CLIPS peptide technology. The companies have agreed to settle all intellectual property disputes worldwide. UndeRHEA-AIneutral
11/12/20 4:01 PMNasdaq : BCYCBicycle Therapeutics to Present at the Jefferies Virtual London Healthcare ConferenceBicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle(R)) technology, today announced that management will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on Thursday, November 19, 2020 at 1:10 p.m. ET. A live webcast of the fireside chat will be accessible in the Investors & Media section ofRHEA-AIneutral
11/05/20 6:59 AMNasdaq : BCYCBicycle Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate UpdateBicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycles(R)) technology, today reported financial results for the third quarter ended September 30, 2020 and discussed recent corporate updates. "Amidst the uncertainty brought on by the COVID-19 pandemic, Bicycle has made significant advances during the third quarter, including the initiRHEA-AIneutral
10/21/20 6:59 AMNasdaq : BCYCBicycle Therapeutics Announces Expansion of Scientific Advisory BoardBicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle(R)) technology, today announced that leaders in the fields of oncology, immunology, pharmacology, and translational research have been appointed to the Company's Scientific Advisory Board (SAB). "It is an honor to welcome Drs. FitzGerald, Grogan, Reis e Sousa, and Swanton, all accRHEA-AIneutral
10/14/20 5:08 PMNasdaq : BCYCBicycle Therapeutics to Present Posters at the SITC 35th Anniversary Annual MeetingBicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle(R)) technology, today announced that preclinical data for BT7480, a tumor-targeted immune cell agonist (TICA(TM)), and an EphA2/CD137 TICA will be presented during an e-poster session at the Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting on November 10-1RHEA-AIneutral
10/01/20 8:06 AMNasdaq : BCYCBicycle Therapeutics Announces Gross Proceeds of $50.0 Million from its At-the-Market Offering Program and Enters into Debt Financing from Hercules CapitalBicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle(R)) technology, today announced that it has completed its at-the-market (ATM) offering program initiated during the third quarter, generating gross proceeds of $50.0 million. Cantor Fitzgerald & Co. and Oppenheimer & Co. Inc. acted as placement agents for the offering. InRHEA-AIneutral
